Kalydeco Dosage
Generic name: ivacaftor
Drug class: CFTR potentiators
Medically reviewed by A Ras MD.
Recommended Adult Dosing
Dosage forms: TAB: 150 mg
Cystic fibrosis
- [150 mg PO q12h]
- Info: for pts w/ ivacaftor-responsive CFTR gene mutations; give w/ fat-containing food
Renal dosing
- CrCl >31: no adjustment; CrCl <31: not defined, caution advised
- HD/PD: not defined, caution advised
Hepatic dosing
- [adjust dose frequency]
- Child-Pugh Class B: 150 mg qd; Child-Pugh Class C: 150 mg qd or less frequently
Recommended Peds Dosing
- Dosage forms: TAB: 150 mg; GRANULE: 25 mg per pkt, 50 mg per pkt, 75 mg per pkt
Cystic fibrosis
- [4-5 mo, >5 kg]
- Dose: 25 mg PO q12h; Info: for pts w/ ivacaftor-responsive CFTR gene mutations; give w/ fat-containing food
- [6 mo-5 yo, 5-6.9 kg]
- Dose: 25 mg PO q12h; Info: for pts w/ ivacaftor-responsive CFTR gene mutations; give w/ fat-containing food
- [6 mo-5 yo, 7-13.9 kg]
- Dose: 50 mg PO q12h; Info: for pts w/ ivacaftor-responsive CFTR gene mutations; give w/ fat-containing food
- [6 mo-5 yo, >14 kg]
- Dose: 75 mg PO q12h; Info: for pts w/ ivacaftor-responsive CFTR gene mutations; give w/ fat-containing food
- [6 yo and older]
- Dose: 150 mg PO q12h; Info: for pts w/ ivacaftor-responsive CFTR gene mutations; give w/ fat-containing food
Renal dosing
- CrCl >31: no adjustment; CrCl <31: not defined, caution advised
- HD/PD: not defined, caution advised
Hepatic dosing
- [4-5 mo, >5 kg]
- hepatic impairment: avoid use
- [6 mo-5 yo, 5-6.9 kg]
- Child-Pugh Class B: 25 mg qd; Child-Pugh Class C: 25 mg qd or less frequently
- [6 mo-5 yo, 7-13.9 kg]
- Child-Pugh Class B: 50 mg qd; Child-Pugh Class C: 50 mg qd or less frequently
- [6 mo-5 yo, >14 kg]
- Child-Pugh Class B: 75 mg qd; Child-Pugh Class C: 75 mg qd or less frequently
- [6 yo and older]
- Child-Pugh Class B: 150 mg qd; Child-Pugh Class C: 150 mg qd or less frequently
SRC: NLM .